OR WAIT null SECS
September 03, 2020
Tight development timelines and accelerated approval pathways favor simple, cost-effective capsule formulations.
September 02, 2020
End-user considerations are becoming increasingly important as they can provide a lot of value and help to ensure commercial success of a drug.
August 03, 2020
This study suggests that using a simple centrifugal method can produce a natural polymer-blend molecule that can successfully be used as an oral delivery mechanism for poorly soluble drugs.
Particle engineering is a useful tool to manipulate API particles into a form that is manufacturable and deliverable to the patient.
Understanding and overcoming excipient variation are crucial for successful continuous processes.
July 08, 2020
The European Commission has approved Lynparza (olaparib) for use in patients with germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer within the European Union.
July 06, 2020
Lonza is making additional investments in its global particle engineering network for expanded capacity and specialized capabilities.
July 02, 2020
The new facility in Grand Rapids, MI, is part of the CDMO’s aggressive expansion plan.
Demand for custom drug delivery solutions is increasing and bringing forth an exciting period of valuable, innovative development opportunities.
Controlled-release formulations offer numerous advantages for developers and patients, and this market is expected to continue to experience growth in the near future.